Annovis Bio (ANVS)
(Delayed Data from NYSE)
$2.64 USD
-0.04 (-1.31%)
Updated Aug 7, 2025 09:52 AM ET
2-Buy of 5 2
D Value B Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ANVS 2.64 -0.04(-1.31%)
Will ANVS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ANVS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ANVS
All You Need to Know About Annovis Bio (ANVS) Rating Upgrade to Buy
Amicus (FOLD) Up as Q2 Earnings & Sales Top, '24 View Updated
ANVS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down
Intra-Cellular (ITCI) Q2 Loss Narrower Than Expected, Sales Beat
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
Other News for ANVS
Annovis Bio completes full patent transfer to crystal buntanetap
Annovis Completes Full Patent Transfer to Crystal Buntanetap | ANVS Stock News
Why Medpace Shares Are Trading Higher By 45%; Here Are 20 Stocks Moving Premarket
Annovis Bio’s Promising Alzheimer’s Study: A Potential Game Changer?
12 Health Care Stocks Moving In Wednesday's Intraday Session